Sign in

    Sanara MedTech (SMTI)

    Q1 2024 Earnings Summary

    Reported on May 14, 2024 (After Market Close)
    Pre-Earnings Price$29.86Last close (May 14, 2024)
    Post-Earnings Price$29.88Open (May 15, 2024)
    Price Change
    $0.02(+0.07%)

    What went well

    • The CEO transition is not expected to disrupt sales momentum, and the team is stronger than ever, indicating continuity and stability in leadership.
    • The company has added two experienced executives to support anticipated higher growth, including Tyler Palmer, who has long-standing experience in wound care, strengthening their management team for future expansion.
    • Sanara anticipates forming partnerships for their Tissue Health Plus value-based care strategy by the end of 2024, which could open up new growth opportunities as they pioneer a novel approach in the wound care market.

    What went wrong

    • The resignation of former CEO Zach Fleming and transition in leadership could lead to potential instability or disruption in strategic direction. While management claims there is "0 disruption," the sudden change may affect the company's momentum.
    • Bone fusion product sales were flat year-over-year, decreasing slightly from $2.6 million in 2023 to $2.5 million in 2024, indicating ongoing challenges in this product line. The company's efforts to re-engage distributors after inventory issues are taking longer than expected.
    • The ambitious Tissue Health Plus strategy depends on forming complex partnerships involving payers, providers, and others, which are still in development. The CEO acknowledges that "no one has ever actually done this" and it is "complicated," suggesting potential delays or difficulties in execution that may impact future growth.

    Q&A Summary

    1. Profitability and SG&A Increase
      Q: Why did profitability decrease despite higher revenue?
      A: Profitability declined due to higher SG&A expenses, which increased faster than revenue quarter-over-quarter. The rise in SG&A is attributed to higher commissions correlated with increased sales and investments in growth opportunities. Additionally, prior year benefits like a credit from the change in fair value of earn-out liabilities and lower amortization of intangibles were not present this year, leading to a higher net loss in 2024.

    2. Impact of CEO Transition
      Q: Has the CEO change disrupted sales momentum?
      A: There has been zero disruption to sales momentum following the CEO transition. The team remains strong, with leadership continuing to drive growth.

    3. Bone Fusion Product Performance
      Q: Why are bone fusion products flat year-over-year?
      A: Bone fusion products experienced softness due to prior inventory issues with ALLOCYTE Plus. Supply disruptions required restarting the process of reengaging distributors, which is taking longer than expected.

    4. Tissue Health Plus Partnerships
      Q: Will partnerships for Tissue Health Plus happen by end of '24?
      A: Yes, partnerships are anticipated by the end of 2024. The company has a comprehensive strategy for value-based wound care and seeks ideal partners to enhance their overall approach.

    5. CEO's Tenure
      Q: Is your role as CEO temporary?
      A: The CEO has no plans to step down anytime soon. He is passionate about the company's mission and is committed to leading the team forward.

    6. New Management Team Additions
      Q: Why did you add two new executives?
      A: The company is anticipating higher growth and needs more personnel. Tyler Palmer was added for Corporate Development with a strategic background, and Jake Waldrop as COO with operational and financial expertise.

    Analyst Coverage

    Research analysts covering Sanara MedTech.